tiprankstipranks
Advertisement
Advertisement

NUVB Stock Latest News

Nuvation Bio granted FDA Fast Track Designation for safusidenib in glioma
The FlyNuvation Bio granted FDA Fast Track Designation for safusidenib in glioma
19h ago
NUVB
Nuvation Bio initiated with an Overweight at JPMorgan
PremiumThe Fly
Nuvation Bio initiated with an Overweight at JPMorgan
3d ago
NUVB
Nuvation Bio Targets Post‑Vorasidenib Glioma With New Safusidenib Trial
PremiumCompany Announcements
Nuvation Bio Targets Post‑Vorasidenib Glioma With New Safusidenib Trial
10d ago
NUVB
Nuvation Bio price target raised to $14 from $12 at B. Riley
PremiumThe Fly
Nuvation Bio price target raised to $14 from $12 at B. Riley
14d ago
NUVB
Nuvation Bio price target raised to $20 from $19 at RBC Capital
PremiumThe Fly
Nuvation Bio price target raised to $20 from $19 at RBC Capital
14d ago
NUVB
Analyst Maintains Buy on Nuvation Bio, Reaffirming $21 Price Target Amid Long-Term IBTROZI Growth Prospects
PremiumRatingsAnalyst Maintains Buy on Nuvation Bio, Reaffirming $21 Price Target Amid Long-Term IBTROZI Growth Prospects
14d ago
NUVB
Nuvation Bio Earnings Call Highlights IBTROZI Surge
Premium
Company Announcements
Nuvation Bio Earnings Call Highlights IBTROZI Surge
14d ago
NUVB
Nuvation Bio reports Q2 EPS (18c), consensus (12c)
Premium
The Fly
Nuvation Bio reports Q2 EPS (18c), consensus (12c)
15d ago
NUVB
Nuvation Bio price target raised to $21 from $17 at H.C. Wainwright
PremiumThe Fly
Nuvation Bio price target raised to $21 from $17 at H.C. Wainwright
25d ago
NUVB
Boris Peaker Reaffirms Buy on Nuvation Bio, Citing Strong Safusidenib Data in IDH1-Mutant Glioma and Expanding Global Commercial Strategy
PremiumRatings
Boris Peaker Reaffirms Buy on Nuvation Bio, Citing Strong Safusidenib Data in IDH1-Mutant Glioma and Expanding Global Commercial Strategy
1M ago
NUVB
RBC looks for Nuvation shares to appreciate as safusidenib data builds
PremiumThe Fly
RBC looks for Nuvation shares to appreciate as safusidenib data builds
1M ago
NUVB
Nuvation Bio announces data from the Phase 2 J201 study
PremiumThe Fly
Nuvation Bio announces data from the Phase 2 J201 study
1M ago
NUVB
Nuvation Bio Moves Safusidenib Into Phase 3, Raising Stakes in Targeted Brain Cancer
PremiumCompany AnnouncementsNuvation Bio Moves Safusidenib Into Phase 3, Raising Stakes in Targeted Brain Cancer
1M ago
NUVB
3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts
Premium
Market News
3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts
1M ago
ABCL
NUVB
Nuvation Bio price target lowered to $19 from $20 at RBC Capital
Premium
The Fly
Nuvation Bio price target lowered to $19 from $20 at RBC Capital
1M ago
NUVB
Nuvation Bio Expands Convertible Notes Offering and Financing
PremiumCompany Announcements
Nuvation Bio Expands Convertible Notes Offering and Financing
2M ago
8K
NUVB
Nuvation Bio Issues Convertible Notes, Retires Secured Debt
PremiumCompany Announcements
Nuvation Bio Issues Convertible Notes, Retires Secured Debt
2M ago
8K
NUVB
Nuvation Bio announces MHRA in UK approves MAA for taletrectinib
PremiumThe Fly
Nuvation Bio announces MHRA in UK approves MAA for taletrectinib
2M ago
NUVB
Nuvation Bio prices upsized offering of $250M of convertible senior notes
PremiumThe Fly
Nuvation Bio prices upsized offering of $250M of convertible senior notes
2M ago
NUVB
Nuvation Bio falls -10.1%
PremiumThe FlyNuvation Bio falls -10.1%
2M ago
NUVB
Nuvation Bio files to sell $200M of Convertible Senior Notes due 2032
Premium
The Fly
Nuvation Bio files to sell $200M of Convertible Senior Notes due 2032
2M ago
NUVB
3 High-Risk, High-Reward Stocks to Buy Now, According to Analysts
Premium
Market News
3 High-Risk, High-Reward Stocks to Buy Now, According to Analysts
3M ago
CATX
GLOO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >